Jim Simons
ZVSA

Jim Simons’s ZyVersa Therapeutics ZVSA Stock Holding History

Jim Simons’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-12,961
Closed -$13.7K – 3906
2024
Q4 		$13.7K Buy
+12,961
New +$20.5K ﹤0.01% 3503

Other funds holding ZVSA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jim Simons's ZVSA Position: Q1 2025 in Review

Jim Simons sold out of ZyVersa Therapeutics (ZVSA) in Q1 2025, closing a stake of 12,961 shares — an estimated $13.7K sold.

Jim Simons first reported a position in ZVSA in Q4 2024 and held it in 1 quarter. The position peaked at $13.7K in Q4 2024. 7 funds tracked by Wall St. Rank hold ZVSA as of Q1 2025.

  • Jim Simons reported no remaining ZyVersa Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Jim Simons sold 12,961 ZyVersa Therapeutics shares in Q1 2025, an estimated $13.7K.
  • Jim Simons first reported a position in ZyVersa Therapeutics in Q4 2024 and held it in 1 quarter.
  • Jim Simons's ZyVersa Therapeutics position peaked at $13.7K in Q4 2024.
  • 7 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q1 2025.

Based on Renaissance Technologies's 13F filing for Q1 2025, filed 14 May 2025.